Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

Oragenics Trading Up 1.7 %

Oragenics stock opened at $0.40 on Thursday. Oragenics has a 1-year low of $0.38 and a 1-year high of $7.74. The firm has a market capitalization of $1.79 million, a PE ratio of -0.05 and a beta of 0.46. The firm’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $1.24.

Oragenics (NYSE:OGEN) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics at the end of the most recent quarter. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.